Skip to main content

Table 2 Clinical characteristics of 19 patients with pneumonitis

From: Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors

Pt

Tumor

sex

Age, year

Agents

ILD

LM

Smoking history

Smoking amount, pack-years

Time to the onset of pneumonitis, day

Grade

Radiographic pattern

1

HNC (Sq)

M

73

NIVO

 − 

 + 

F

67.5

112

1

OP + NSIP

2

HNC (Sq)

M

79

NIVO

 + 

 − 

F

57

42

1

OP + NSIP

3

HNC (Undifferentiated)

M

68

NIVO

 + 

 + 

F

48

87

2

NSIP

4

HNC (Sq)

po

66

NIVO

 − 

 + 

C

22.5

59

1

OP + NSIP

5

HNC (Sq)

M

71

NIVO

 − 

 − 

F

40

6

1

OP

6

HNC (Sq)

M

69

NIVO

 − 

 + 

C

50

111

5

NSIP

7

MM

F

78

NIVO

 − 

 − 

N

0

105

1

OP

8

GC (AdSq)

M

72

NIVO

 − 

 + 

C

26.5

456

2

NSIP

9

GC (Ad)

M

58

NIVO

 − 

 + 

C

36

20

1

OP

10

GC (Ad)

M

81

NIVO

 − 

 + 

F

15

287

1

HP

11

RCC (clear cell)

M

74

NIVO

 − 

 + 

F

36.75

771

2

NSIP

12

RCC (clear cell)

M

54

NIVO

 − 

 + 

C

16

371

2

OP

13

RCC (clear cell)

M

63

NIVO

 − 

 − 

F

64.5

105

2

OP

14

RCC (clear cell)

F

64

NIVO

 − 

 + 

N

0

25

2

OP

15

RCC (clear cell)

M

73

NIVO

 + 

 + 

F

22.5

129

2

OP

16

RCC (clear cell)

M

53

NIVO

 − 

 + 

N

0

1068

2

NSIP

17

UC

M

69

PEM

 + 

 + 

C

12

2

5

NSIP

18

UC

M

64

PEM

 − 

 + 

F

102

343

3

OP

19

UC

M

69

PEM

 − 

 + 

F

190

229

2

OP

  1. Ad Adenocarcinoma, C Current, F Female, F Former, GC Gastric cancer, HNC Head and neck cancer, HP hypersensitivity pneumonitis, ILD Interstitial lung disease, LM Lung metastasis, M male, MM Malignant melanoma, N Never, NIVO Nivolumab, NSIP Nonspecific interstitial pneumonia, OP Organizing pneumonia, PEM Pembrolizumab, RCC Renal cell carcinoma, Sq Squamous carcinoma, UC Urothelial carcinoma